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Binding of interleukin-2 (IL-2) to high affinity receptors on ac-
tivated normal T cells was shown to be the essential step in 
induction of proliferation of such cells. The finding of abundant 
IL-2 receptors on malignant T cells in adult T cell leukemia sug-
gested a deregulation of the IL-2 IL-2 receptor system and was 
assumed to account for aberrant growth in malignant disorders 
of T cells. In this study we use malignant T cells from nine 
patients with the clinical diagnosis of T-ALL or T-NHL and did 
not detect IL-2 dependent growth under conditions in which 
normal T cells responded to IL-2. IL-2 receptors comparable in 
numbers to activated T cells were found on T-ALL T-NHL cells 
stimulated with PHA and PMA. However, binding studies using 
radiolabeled IL-2 indicated that the receptors present on malig-
nant T ceils were not able to bind to IL-2 with high affinity. 
Therefore, if IL-2 is involved in the proliferation of malignant T 
cells, its mechanism of growth regulation may be different from 
the one for normal T cells. Alternatively, IL-2 may not play a role 
in the regulation of growth of malignant T cells in vitro. 
INTRODUCTION 
AFTER activation by antigen or mitogen, T cells secrete .interleukin-2 (IL-2), express IL-2 receptors, and subse-
quently start to proliferate (1-3). Thus, proliferation of acti-
vated clones is mainly dependent on a single growth factor (IL-
2) and its membrane receptor. The expression of IL-2 receptors 
on activated T cells is detected by monoclonal antibodies against 
epitopes of the IL-2 receptor molecule (4-6). Recently, it has 
been shown that the IL-2 receptor consists of at least two chains 
with molecular weights of 55 kd (Tac protein) and 75 kd, 
respectively (7-11). Only the p55 chain is recognized by anti-
Tac antibodies initially used to define the IL-2 receptor (6). 
However, proliferation of activated T cells requires high affin-
ity binding of IL-2 which only takes place if both chains of 
the receptor are expressed (9, 10). 
The IL-2 dependent growth control of mature normal T cells 
suggests a role of IL-2 also for abnormal proliferation in T cell 
leukemias and non-Hodgkin's lymphomas (NHL) of T cell 
type. In these cases rapid proliferation of malignant cells leads 
to considerable tumor masses in bone marrow, the thymus, and 
lymphatic organs. It was originally postulated that a deregu-
lation of the IL-2/IL-2 receptor system was involved in the 
proliferation of adult T cell leukemia/lymphoma (ATL) induced 
by H T L V I (12, 13). In fact, using the anti-Tac antibody, A T L 
cells have been found to express about 10 times more IL-2 
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receptors than stimulated T cells (14, 15). However, so far 
only in a few cases of A T L IL-2 dependent growth of malignant 
cells have been demonstrated (16). On the other hand, in a 
semisolid agar culture system, IL-2-mediated proliferative re-
sponse of T - A L L / N H L cells has been demonstrated (17). 
We compared IL-2 receptor expression and IL-2 respon-
siveness of T - A L L / T - N H L cells with that of normal T cells. 
Our data show that the malignant T cells could easily be induced 
to express IL-2 receptors detected by monoclonal antibodies 
after stimulation with phytohemagglutinin (PHA) and phorbol-
myristate-acetate (PMA). However, in contrast to normal T 
cells, significant IL-2 dependent growth or increase in cell 
numbers did not occur in a standard liquid culture system. 
Further studies showed that the IL-2 receptors present on stim-
ulated malignant T cells did not bind to IL-2 with high affinity. 
MATERIALS AND METHODS 
Patient Data and Isolation of Malignant T Cells. A summary of the 
patient data including phenotyping of the malignant cells is shown in 
Table 1. Malignant cells were isolated from the different sources in-
dicated by standard Ficoli-Hypaque (Pharmacia. Freiburg. F.R.G.) 
centrifugation and stored frozen in liquid nitrogen in medium con-
taining 20c/c FCS and 10% DMSO. Only samples containing more 
than 95c/c blast cells, based on morphologic examination and pheno-
typing, were included in the study. The phenotypes of freshly isolated 
and thawed cells were identical. The viability of thawed cells was 
greater than 95%. All patients were included in the German BFM 
A L L / N H L therapeutic protocols, and phenotyping of T - A L L / N H L was 
confirmed by the study's reference typing laboratory (Divison of He-
matology, Klinikum Steglitz. West Berlin, F.R.G.) . 
A L L patients exhibited the typical clinical picture of T - A L L / N H L 
with enlarged lymph nodes and mediastinal mass. Discrimination be-
tween A L L and NHL was made on the basis of bone marrow involve-
ment. 
Isolation of T Cells from Donor Blood. T cells were isolated from 
the mononuclear cell fraction of peripheral blood after Ficoli-Hypaque 
centrifugation by rosetting with sheep erythrocytes treated with 2-
aminethylthiouroniumbromide (AET) as described (18). Briefly, cells 
were incubated with A E T treated sheep erythrocytes, and rosettes were 
isolated by Ficoli-Hypaque centrifugation. Erythrocytes in the sedi-
mented fraction were removed by hypotonic lysis in distilled water 
for 5 sec followed by reconstitution to normal osmolarity using excess 
culture medium. 
Monoclonal Antibodies (MoAb) and Immunofluorescence. Mo Abs 
reactive with T i l , T3, T4, T8 antigen were purchased from Ortho 
Diagnostics (Neckargemünd, F.R.G.) and used according to the man-
ufacturer's instruction. The pan-T antibody Leu-1 and Leu-9, an an-
tibody reactive with all T - A L L cells, corresponding to the WT1 antibody 
(19, 20), were purchased from Becton-Dickinson (Heidelberg, F.R.G.). 
Control antibodies not listed in Table 1 included anti-HLA-DR (Bec-
ton-Dickinson), anti-CALLA (J5, Coulter Electronics, Krefeld, F.R.G.), 
and the B cell specific antibodies HD 37 (CD 19) and HD 39 (CD22) 
provided by Dr. B. Dörken (Medizinische Universitäts-Poliklinik, Hei-
delberg). The MoAb against the IL-2 receptor (anti-Tac) was kindly 
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Patient No. 
Age 
(yr) 
% Positive Cells 3 
Sex 
Leu-9 Leu-1 T11 T4 T8 T3 IL-2rec ö 
Classification 
of ALL/NHL C 
Cell 
Source 0 
Z . M . 1 8 Male 95 98 3 1 1 2 0 I (NHL) L N C 
H.D. 2 8 Male 96 21 4 1 3 3 1 I (ALL) P B L 
M.C. 3 13 Male 90 25 19 1 8 1 1 I (ALL) B M 
B.C. 4 7 Male 56 72 56 4 7 12 0 I (ALL) P B L 
M.F. 5 5 Male 88 76 94 25 10 4 1 II (NHL) P E 
B .M. 6 31/2 Female 66 65 95 56 93 5 1 II (ALL) B M 
L B . 7 7 1 / 2 Male 96 88 93 90 56 4 1 II (NHL) P E 
L O . 8 10 Male 68 65 79 35 68 62 1 III (NHL) P E 
Z .M . 9 13 Male 93 92 53 14 95 71 1 III (ALL) B M 
Control T cells 
( A E T - E " ) e 73 68 86 62 23 71 3 
a T h e phenotyping of leukemic cells was performed as described in Material and Methods. 
fcThe presence of IL-2 receptors (anti-Tac) was determined on freshly isolated, unstimulated cells. 
c T h e differentiation between A L L and NHL was made on the basis of bone marrow involvement (>25% blast cells). 
d C e l l sources were: L N C , lymph node cells; P B L , peripheral blood cells; B M , bone marrow cel ls; P E , pleural effusion cells. All cell populations studied contained 
more than 9 5 % blast cells. 
e Contro l T cells were prepared by rosetting with AET-treated sheep red blood cells as indicated in Material and Methods; the purity of isolated T cell population 
always exceeded 95%. 
provided by Dr. T. Waldmann, National Cancer Institute, and was 
used in 1:20 dilution of the purified antibody preparation. 
Surface markers were assayed by indirect immunofluorescence using 
affinity purified FITC labeled goat anti-mouse IgG after incubation of 
1 x 106 cells/ml with the respective MoAbs. Stained cells were either 
identified by immunofluorescence microscopy (Zeiss, F.R.G.) or by 
FACS analysis (Ortho Diagnostics). 
Cell Culture and Proliferation Assay. The standard culture medium 
for all assays was RPMI 1640 (Gibco, Grand Island, NY) supple-
mented with L-glutamine (2 I H M final concentration), streptomycin 
(100 |xg/ml), penicillin (100 U/ml), HEPES buffer (25 m M final con-
centration), and 10% fetal calf serum (FCS) (Cat. No. 20017, Conco 
Lab-Division, Wiesbaden, F.R.G.) . All cell cultures were performed 
at 37°C in air with 5% C 0 2 and at 90% relative humidity. 
For the assessment of proliferative responses, cells were cultured 
for 3 days in 96-well flat bottom plates (Costar, Darmstadt, F.R.G.) 
in the presence of irradiated (3,000 rad) peripheral blood mononuclear 
cells (1 x lOVwell) as a feeder layer. Stimulation included 1 p,g/ml 
PHA (PHA-P, Wellcome, Burgwedel, F.R.G.) and 10 ng/ml PMA 
( 12-o-tetradecanoylphorbol-13-acetate, Sigma, Munich, F.R.G.). Re-
combinant IL-2 (r-IL-2 100 U/ml), kindly provided by Biogen S.A., 
Geneva, was added to some cultures. For the last 8 hr of culture 0.5 
uCi 3H-thymidine ( 3H-TdR, specific activity 25 C i / m M , Amersham, 
Braunschweig, F.R.G.) was added. Incorporation of 3 H-TdR was mea-
sured using standard liquid scintillation procedures. 
Induction of IL-2 Receptor Expression. 1 x 106 cells/ml were cul-
tured for 48 hr in the presence of 1 jxg/ml PHA and 10 ng/ml PMA, 
washed twice, and assayed for IL-2 receptor expression as indicated. 
IL-2 Dependent Growth of Activated Cells. After activation by PHA 
and PMA, as described in the last paragraph, cells (1 x lOVwell) 
were cultured in 96-well flat bottom plates for 24 hr in the presence 
of IL-2 (100 U/ml) and 0.5 uCi 3 H-TdR to assess proliferation. 
In addition, activated cells were cultured in a concentration of 1 x 
lOVml in 24-well plates (Costar, Darmstadt, F.R.G.) in the presence 
of r-IL-2 (100 U/ml) for 1 week. On day 4 additional IL-2 (100 U/ 
ml) was added to the cultures. The proliferative response was assessed 
by counting viable cells (trypan blue exclusion) on day 4 and day 7. 
I25J-IL-2 Binding Assay. Normal and malignant T cells were stim-
ulated for 48 hr with PHA and PMA as described before. After ex-
tensive washing in RPMI 1640 without FCS, cells were incubated two 
times at 37°C for 1 hr in culture medium without FCS and washed 
again. For IL-2 binding, 80 u-1 containing 1 x 106 cells in RPMI 
1640 + 1% bovine serum albumin (BSA) were incubated with 10 fxl 
125J-labeled IL-2 (NEN, Boston, MA) in 1.5-ml Eppendorf tubes to 
give final concentrations ranging from 1 pM to 500 pM , 2 5J-IL-2. In 
order to determine specific binding, parallel tubes included a 100-fold 
excess of cold r-IL-2. Incubation was done at 40°C for 1 hr. After 
incubation, cells were centrifuged at 10,000 x g for 30 sec, resus-
pended, and centrifuged through a 200 fil layer of a mixture of 77% 
dibutylphthalate and 23% olive oil for 90 sec at 10,000 x g. The tips 
of the tubes containing the cell pellet were cut off, and the radioactivity 
was measured in a gamma counter. Specific binding was calculated 
by subtracting activity bound in the presence of excess cold IL-2 (100-
fold) from total binding. 
RESULTS 
Clinical Data and Phenotype of T-ALL/NHL Cells. Table 1 
summarizes the clinical data and the surface phenotype of ma-
lignant cells from the patients included in this study. The MoAbs 
used for phenotyping had been selected because they define 
distinct stages of T-cell differentiation (see ref. 19). The pan 
T antibodies Leu-1 (CD5) and Leu-9 (CD7) were used as the 
most sensitive markers for T - A L L (20). The classification of 
T - A L L / N H L cells was made according to a recently published 
proposal (19). In group I the antigens found on mature T cells 
(T3, T4, T8) are not expressed. Group II is defined by coexpres-
sion of T4 and T8 antigens and limited expression of the T3 
complex representing the antigen recognition complex of ma-
ture T cells. In group III segregation of T4 and T8 antigens 
occurs, and T3 is fully expressed. In all samples used for this 
study, more than 95% of the cells were blasts on the basis of 
morphologic examination. In cases 4, 8, and 9, a low contam-
ination by normal T cells could not be excluded by phenotyping. 
However, stimulation by conventional T-cell mitogens (Table 
2 and data not shown) did not induce proliferation in these 
cells. 
Proliferative Response of Stimulated T-ALL/NHL Cells. In 
order to study the proliferation of malignant T cells induced 
by a T cell mitogen, normal T cells and A L L / N H L cells were 
stimulated with PHA for 72 hr. To reduce possible limiting 
factors during the culture, an excess of IL-2 (100 U/ml) and 
irradiated mononuclear cells as a source of other cytokines were 
added. As shown in Table 2, in contrast to normal T cells, no 
significant proliferative response could be induced in T - A L L / 
N H L cells. 
Segregation of IL-2 Receptor Expression and IL-2 Respon-
siveness of Malignant T Cells. We next addressed the question 
as to whether IL-2 receptors are present on stimulated malignant 
T cells. For normal T cells, stimulation with the combination 
of PHA and P M A usually induces maximal IL-2 receptor 
expression. Our initial experiments have shown that this com-
bination is also the most effective for induction of Tac expres-
Table 2. PHA Stimulation and IL-2 Response of T-ALL NHL Cells 
(72-Hr Culture) 
Cells Incubated with 
Patient No. 
Medium PHA + IL-2 
1 ND ND 
2 120 530 
3 2,070 3,180 
4 5,830 5,270 
5 4,590 4,880 
6 1,250 2,290 
7 610 600 
8 3,110 4,910 
9 1,610 3,030 
Control 
T cells 1,320 32,420 
1 x 105 cells were incubated in flat bottom microtiter plates in the presence 
of feeder cells (1 x 105/well) or in the presence of feeder cells plus 1 u.g/ml 
PHA and 100 U/ml r-IL-2 for 72 hr. Proliferation was measured after an 8-hr 
pulse with 3H-TdR before harvesting. Data are expressed as the mean cpm 
of triplicate cultures with a SD of less than 10%. ND = not done. 
sion on T - A L L / N H L cells. After 48 hr of incubation, Tac 
expression is optimal, and further incubation leads to a signif-
icant increase in the number of dead cells in the malignant cell 
population (Table 3). As shown in Table 1, freshly isolated 
unstimulated malignant cells do not express IL-2 receptors. 
However, with one exception (patient 5), after stimulation with 
PHA and P M A , a significant number of IL-2 receptor positive 
cells were found, using the anti-Tac Mo Ab (Table 4). Sur-
prisingly, in a short term assay these IL-2 receptor positive 
cells did not show a significant proliferative response compa-
rable to normal T cells (Table 5) when cultured in the presence 
of 100 U/ml r-IL-2. The maximal response was 9-fold (patient 
9) in contrast to the 250-fold response observed with normal 
T cells. 
Three of the malignant T cell populations (nos. 1, 3, and 9) 
showed IL-2 receptor expression comparable to normal T cells 
with respect both to the number of positive cells and fluores-
cence intensity of individual cells (Table 4 and Fig. 1). How-
ever, in a 1-week liquid culture system, activated cells from 
these patients died in the presence of IL-2 (100 U/ml), whereas 
activated normal T cells showed a 20-30-fold increase in cell 
numbers (Fig. 2). The number of viable cells and dead cells 
together in the cultures of the malignant cells did not exceed 
the initial number of cells placed in culture, indicating that no 
exhaustive proliferation with a high number of dead cells oc-
curred. 
125J-IL-2 Binding to Stimulated Normal and Malignant T 
Cells. The data shown before suggested that the IL-2 receptor 
expression on malignant T cells defined by the anti-Tac anti-
body was distinct from that on normal T cells. Therefore, IL-
2 binding assays were performed using the stimulated cells 
from the patients with the highest Tac expression (nos. 1,3, 
and 9). 
Table 3. Kinetic of PHA + PMA Induced IL-2 Receptor Expression 
Patient No. 
% Tac-Positive cells (% Viable Cells) 
24 Hr 48 Hr 72 Hr 
1 70 (95) 84 (91) 80 (48) 
3 32 (97) 80 (95) 78 (54) 
T cells 60 (92) 70 (95) 75 (87) 
Normal and malignant T cells were incubated (1 x 106/ml) for the times 
indicated (hrs) in the presence of PHA (1 |xg/ml) and PMA (10 ng/ml). The IL-
2 receptor positive cells were detected by indirect immunofluorescence with 
the anti-Tac antibody and 200 cells were counted. Viability was simulateously 
assessed by trypan blue exclusion. 
Table 4. Induction of IL-2 Receptor Expression of T-ALL/NHL Cells by 
PHA + PMA (48 Hr) 
% Positive Cells 
Patient No. 
Unstimulated Stimulated 
1 1 87 
2 4 18 
3 1 89 
4 1 40 
5 1 8 
6 5 28 
7 4 24 
8 6 12 
9 1 45 
Control 
T cells 5 57 
Normal and malignant T cells were incubated (1 x l06/ml) for 48 hr in the 
presence of PHA (1 u.g/ml) and PMA (10 ng/ml). The IL-2 receptor positive 
cells were detected by indirect immunofluorescence with the anti-Tac antibody, 
and 200 cells were counted. 
As shown in Fig. 3, high affinity binding of 1 2 5 J-IL-2 was 
found in normal T cells stimulated with PHA plus P M A in the 
range of concentrations expected from the literature (1, 22, 23) 
with about 5,000-7,000 high affinity binding sites per cell. In 
contrast, the stimulated malignant T cells did not exhibit sig-
nificant high affinity binding sites. 
In preliminary experiments using IL-2 concentrations in the 
nM range, low affinity binding was observed (data not shown). 
Thus, the presence of the Tac antigen and the absence of high 
affinity binding sites suggest that only the p55 chain of the IL-
2 receptor is expressed by the malignant T cells. 
DISCUSSION 
The proliferation of mature T cells activated by antigen or 
mitogen depends mainly on the presence of IL-2 as a growth 
factor and the expression of IL-2 receptors on the responding 
cell population. When IL-2 receptors are continuously ex-
pressed, T cells can be kept in culture growing for weeks or 
even months. The availability of recombinant IL-2, as well as 
monoclonal antibodies recognizing the IL-2 receptor, has al-
lowed detailed studies of ligand receptor interaction (22-24). 
IL-2 was demonstrated to be bound by high affinity receptors 
(kd = 10" 1 1 M ) on activated T cells (1, 23). Monoclonal an-
tibodies such as anti-Tac which block IL-2 binding appear to 
recognize a 55-kd peptide as part of the IL-2 receptor (25-28). 
However, the number of Tac binding sites on activated T cells 
was always found to exceed the number of IL-2 high affinity 
binding sites (22, 23). Using a 1,000-fold increase of the IL-
2 concentration, binding of IL-2 to the receptors defined by 
anti-Tac could be demonstrated. This led to the definition of 
Tac as the low affinity receptor and the combination of Tac 
Table 5. Proliferation of Activated Normal and Malignant T Cells 
in the Presence of IL-2 
Treatment of Cells 
Patient No. 
Unstimulated (cpm) Stimulated (cpm) 
2 296 1,357 
5 671 1,845 
6 564 4,817 
7 1,221 6,293 
9 322 2,840 
Control 
T cells 199 49,418 
Normal and malignant T cells activated by PHA (1 u-g/ml) and PMA (10 ng/ 
ml) for 48 hr were cultured (1 x 105/well) in the presence of IL-2 (100 U/ml) 
and 3 H-TdR for 24 hr. Data are given as mean cpm of triplicate cultures with 
a SD of less than 10%. 
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Figure 1. Comparison of Tac expression of stimulated normal and 
malignant T cells. Normal T cells (A) and malignant T cells (1 x 106 ml) 
from patient no. 1 (B), no. 3 (C), and no. 9 (D) were incubated for 48 hr 
with PHA (1 ng/ml) and PMA (10 ng/ml). Subsequently, IL-2 receptor 
expression was assessed by indirect immunofluorescence with the anti-
Tac antibody and analyzed by flow cytometry (FACS). Data are given as 
fluorescence intensity versus relative cell numbers. 
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Figure 2. IL-2 induced proliferation of stimulated normal and malig-
nant T cells. PHA + PMA stimulated cells prepared as described in Figure 
1 for immunofluorescence analysis were cultured (1 x 105/ml) in the 
presence of r-IL-2 (100 U/ml). On day 4 cells were counted and r-IL-2 (100 
U/ml) was again added to the cultures. Proliferation was assessed by 
counting viable cells on the days indicated. A, T cells; B, patient 1; 
C, patient 3; D, patient 9. 
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Figure 3. Binding of radiolabeled IL-2 to stimulated normal (•) and 
malignant T cells. Normal (•) and malignant T cells from patients 1 (O), 
3 (A), and 9 (•) were stimulated to express IL-2 receptors by incubation 
with PHA and PMA as described (Fig. 1). Subsequently, stimulated cells 
were tested for IL-2 receptor expression by immunofluorescence and 
used for binding of 12SJ-IL-2 as described in Material and Methods. Num-
ber of Tac positive cells in this experiment: T cells, 65%; no. 1,85%; 
no. 3, 61%; no. 9, 63%. 
and a postulated second component as the high affinity IL-2 
receptor (22, 23). 
Recently, the second component of the IL-2 receptor (7 ,9 , 
10) could be identifed as a 75-kd protein which together with 
the 55-kd peptide combines to give a fully active high affinity 
receptor (8, 10). Only the coexpression of the 55-kd and 75-
kd peptides appears to mediate IL-2 induced proliferation in 
mature T cells. 
It was attractive to consider a deregulated IL-2/IL-2 receptor 
system as the cause of abnormal growth regulation in malignant 
T cells. In particular, continuous expression of IL-2 receptors, 
autocrine mechanisms assuming simultaneous production of IL-
2 and IL-2 receptor expression, have been discussed (12, 13, 
29). This hypothesis has been stimulated mainly by the dem-
onstration of excess numbers of IL-2 receptors on leukemic T 
cells in A T L induced by human T leukemia virus type I (HTLV I) 
(12, 13, 30). However, freshly isolated cells express mainly 
low affinity receptors, do not secrete IL-2, and poorly respond 
to exogenous IL-2 (31, 32). On the other hand, infection of T 
cells by HTLV-I leads to disturbance of the IL-2/IL-2 receptor 
system, which may result in IL-2 dependent autonomous growth 
(33, 34). In addition, IL-2 dependent growth of malignant cells 
has been described in rare cases of A T L (16, 35). In contrast 
to A T L , where cells taken from patients can be maintained in 
vitro, the malignant T cells in T - A L L or T-NHL not induced 
by HTLV-I rapidly die in vitro despite extensive proliferation 
in vivo. 
This situation strongly suggests a lack of growth factor(s) 
during the in vitro culture. Recently, Touw et al. demonstrated 
induction of IL-2 receptors and IL-2 dependent colony for-
mation in a semisolid agar culture system with malignant cells 
from children with T - A L L or T-NHL (17). 
In our study of malignant T cells from nine patients with T-
A L L or T-NHL of various differentiation stages, we found 
expression of IL-2 receptors as defined by the presence of anti-
Tac similar to normal T cells after stimulation with PHA and 
P M A (Table 3). The number of receptor positive cells in two 
cases with early T cell phenotype (nos. 1 and 3) even exceeded 
that usually found with stimulated normal T cells. However, 
compared to normal T cells, no net gain in viable cells in vitro 
was induced by the addition of excess r-IL-2 to these strongly 
IL-2 receptor positive T - A L L / N H L cells (Fig. 2). The minimal 
responses observed in the short term culture system could be 
due to a very low fraction of responding cells or to contami-
nation with normal T cells. If one considers the minimal 3 H -
TdR uptake in Table 5 as indicative for a low fraction of 
responding cells, IL-2 is apparently not able to induce long 
term growth (Fig. 2) in the vast majority of IL-2 receptor 
positive cells. The production of growth inhibiting factors by 
stimulated leukemia cells has to be considered; however, su-
pernatants of the T - A L L / N H L cells stimulated with PHA and 
P M A did not suppress the proliferation of IL-2 dependent T 
cell lines or mitogen activated T cells (data not shown). 
Our binding studies using radiolabeled IL-2 offer a possible 
explanation for the lack of IL-2 responsiveness by demonstrat-
ing that no high affinity binding sites were present on activated 
T - A L L / N H L cells in three cases with high percentage of Tac-
positive cells. Thus, the IL-2 receptor on IL-2 receptor positive 
malignant T cells is a low affinity receptor (defined by the anti-
Tac antibody) which is not able to mediate IL-2 dependent 
growth. The data may indicate that the 75-kd chain of the 
receptor is missing on T - A L L / N H L cells since the expression 
of the Tac peptide alone is considered to be insufficient for 
growth induction in T cells (36-38). 
To further document the absence of the 75-kd peptide, cross-
linking studies of the IL-2 receptor using the anti-Tac antibody 
would be useful. These studies, however, would require cell 
numbers (10 8 cells) which are obviously not available from 
patient samples. 
Recent data by Rubin et al. (39) suggest that under certain 
conditions the expression of the Tac peptide alone is sufficient 
at least to transmit stimulatory signals by IL-2. Using mouse 
L cells transfected with the gene encoding the Tac peptide, 3 H -
thymidine uptake and D N A synthesis could be demonstrated 
in response to IL-2 in individual cells. However, the percentage 
of responding cells has not been estimated, and IL-2 dependent 
growth has not been demonstrated. 
In our experiments we were not able to confirm the results 
of Touw et al. (17), which have been obtained in a semisolid 
culture system, showing proliferation of malignant T cells lower 
(4-30-fold) than but comparable to normal T cells in response 
to mitogens and IL-2. They even found one case with a mature 
phenotype responding to PHA plus IL-2 in the same way as 
normal T cells. However, in repeated experiments we have not 
seen significant proliferation in our two patients with stage III 
A L L / N H L in response to IL-2. 
In summary, our data argue against a role of IL-2 in T - A L L / 
N H L growth similar to the one for normal T cells. First, freshly 
isolated malignant T cells do not express IL-2 receptors, and 
IL-2 does not induce or maintian growth in vitro. Second, T-
A L L / N H L cells induced by compounds thought to mimic phys-
iological stimuli (PHA and phorbol ester) do express IL-2 re-
ceptors but do not show an increase in cell numbers in response 
to IL-2 as normal T cells do under the same conditions. Third, 
the IL-2 receptors on the malignant T cells investigated do not 
show high affinity binding characteristics and thus do not rep-
resent functionally active IL-2 receptors. It cannot be excluded, 
however, that intracellular IL-2 which may be produced by 
malignant T cells is active. In addition, certain culture con-
ditions or conditions found in vivo may facilitate the additional 
expression of the 75-kd receptor protein. Thus, further studies 
are necessary to study the regulation of expression of the 75-
kd protein to define the role of IL-2 in growth regulation of 
malignant T cells not induced by HTLV-I . Alternatively, other 
growth factors acting on T cells such as interleukin-4 have to 
be considered to be involved in the induction and maintenance 
of growth of malignant T cells (36, 37). 
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